Improving direct pharmacist counseling rates for oral oncolytic medications at an outpatient oncology clinic

Background: Because of the increasing prevalence of the use of oncolytic orally to patients with malignancies, implementation and monitoring strategies to improve patient safety has become a necessity. Our focus is on the American Society of Oncology Quality Oncology Practice Initiative (QOPI) clinical standards of care, standards of 2.3, and the need for counseling patients before the first administration of oral oncolytic therapy.

Objective: To assess the implementation of strategies for improving the workflow to determine their effect on the number of patients reached for pharmacist counseling prior to the first dose of oral oncolytic drugs.
Methods: In this study a quasi-experimental quality improvement, we formed a multidisciplinary group to develop and implement processes workflow improvements. This process is focused on the redistribution of workflow and application of new technology in EPIC Beacon.

Results: A total of 86 patients were identified as eligible for counseling (38 pre-intervention, post-intervention 48). There was a statistically significant increase in the number of eligible patients counseled in the post-intervention period compared to the pre-intervention period (100% vs 86.84%; 95% CI = -0.212, -0.205; P = 0.017). No significant difference was observed in the number of in-person advising patients or advising patients before the first dose.

Conclusion: Our intervention shows the level of 100% of the advice in the post-intervention period. Further work needs to be done to increase the number of patients we reach before they take their first dose of the drug, as well as the number of patients we can advice face to face.

The relationship between in-line filtration and Type I hypersensitivity reactions in pediatric oncology patients who receive intravenous etoposide

The purpose of this study was to describe hypersensitivity reactions with and without the use of in-line filter for intravenous etoposide therapy in pediatric oncology patients. This is a retrospective review of all patients who were treated in the Division of Oncology / Hematology / Bone Marrow Transplant at Children’s Hospital of British Columbia with intravenous etoposide between December 1, 2013 and February 1, 2018. hypersensitivity and anaphylactic reactions associated with infusion of etoposide compared over time, including 12 months earlier, 27 months for use, and for 12 months after the cessation of in-line filtration.

There were 192 patients (average age of 6.0 (IQR 2.8 to 13.0) years were treated with etoposide and etoposide infusion 486 including 137 (28%) previously, 261 (54%) for and 88 (18%) after use filter in-line at our center. twenty-six of 486 (5%) and 13/486 (3%) of infusions resulted in type I hypersensitivity reactions and anaphylaxis, respectively.

There were 2/137 (1%), 36 / 261 (14%.) and 1/88 (1%) infusion reactions before, during and after an in-line filter, each infusion reaction during the period-line filter is higher than during the pre-filter (Z = 3.978; p <0.001) and post-filter (Z = 3.335 ;. p <0.001) in the period of research data show that the use of in-line filtration may be associated with an increased frequency of hypersensitivity reaction to etoposide in pediatric cancer patients.

 Improving direct pharmacist counseling rates for oral oncolytic medications at an outpatient oncology clinic
Improving direct pharmacist counseling rates for oral oncolytic medications at an outpatient oncology clinic

Why Racial Justice Matters in Radiation Oncology

The recent events have reaffirmed that racism is a pervasive disease disrupt the United States and the infiltration of the fabric of this nation. As health care professionals dedicated to understanding and reduce disease, many radiation oncologists have failed to recognize how structural racism affect the health and well-being of patients we aim to serve. Literature is full of descriptive statistics which show a higher incidence and mortality experienced by the Black population’s health conditions ranging from infant mortality to infectious diseases, including the coronavirus disease in 2019 (COVID-19).

The recognition that the roots of health inequalities experienced by Black people in this country based on racism is essential to move the nation and advanced the field of radiation oncology. With this lens, a brief overview of the structural and institutional racism shape the discussion about what radiation oncologists and their representative organizations can do to cope with this disaster. As a member of the technology, we often use the power of data to improve human health and disease challenge with optimism that approach multidisciplinary effort can result in healing. Some principles to reduce the old problem of the Black marginalization in the field has been recommended by ATIP (Recognition, transparency, intentionality, and representation) and lead (Learn, Engage, Advocate, Advocate, Support) approach.

However, additional introspection recommended. Just like individuals, practices and organizations rallied to determine how best to address the problems associated with the 19th COVID pandemic, studied the same spirit should be applied to the issue of racism to combat this evil and often deadly disease.

Nurse-led oral and maxillofacial oncology clinic: a review

The oral and maxillofacial (OMFS) head “nurse-led” and neck (H & N) clinics have been introduced and developed over the last decade, and we are now close to the point that this effort could potentially be applied nationally. This paper is a systematic review of the proposed clinical models OMFS H & N nurse-led.

Peptide YY (PYY) (Human) - Antibody

H-059-01 100 μl
EUR 469.8

Peptide YY (PYY) (Human)

059-01 200 μg
EUR 119.88

Anti-Inflammatory Peptide 1

004-01 200 μg
EUR 27

Anti-Inflammatory Peptide 2

004-02 200 μg
EUR 27

Anti-Inflammatory Peptide 3

004-03 200 μg
EUR 27

Peptide YY (PYY) (3-36) (Human) - Antibody

H-059-02 100 μl
EUR 604.8

VEGF (125-136) (Human)

007-57 100 μg
EUR 158.76

Anti-Angiogenic Peptide Library

L-008A 88 peptides
EUR 6067.44

GnRH Associated Peptide (GAP) (1-13) / GnRH Precursor Peptide (14-26) (Human)

029-03 500 μg
EUR 114.48

GnRH Associated Peptide (GAP) (1-24) / GnRH Precursor Peptide (14-37) (Human)

029-04 100 μg
EUR 114.48

GnRH Associated Peptide (GAP) (1-53) / GnRH Precursor Peptide (14-66) (Human)

029-05 20 μg
EUR 267.84

GnRH Associated Peptide (GAP) (25-53) / GnRH Precursor Peptide (38-66) (Human)

029-06 100 μg
EUR 114.48

Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - Antibody

H-064-07 50 μl
EUR 238.68

Peptide YY (PYY) (3-36)-Gly (Human) - Antibody

H-059-08 100 μl
EUR 469.8

Galanin-Like Peptide (GALP) (Human) - Antibody

H-026-51 50 μl
EUR 604.8

[Cys0]-Peptide YY (PYY) (3-19) (Human) - Antibody

H-059-16 100 μl
EUR 469.8

[Cys20]-Peptide YY (PYY) (3-19) (Human) - Antibody

H-059-17 100 μl
EUR 469.8

Peptide-Depleted Plasma (Human)

MB-099-01 2 ml
EUR 119.88

Peptide YY (PYY) (Human) - Purified IgG Antibody

G-059-01 400 μg
EUR 438.48

Peptide YY (PYY) (3-36) (Human)

059-02 200 μg
EUR 102.6

Gastrin Releasing Peptide (GRP) (Human) - Antibody

H-027-07 50 μl
EUR 238.68

Stresscopin Related Peptide (SRP) (Human) - Antibody

H-019-27 50 μl
EUR 604.8

C28 optimized peptide 6 (Human)

073-82 100 μg
EUR 235.44

Peptide YY (PYY) (Human) - EIA Kit

EK-059-01 96 wells
EUR 617.76

Peptide YY (PYY) (Human) - RIA Kit

RK-059-01 125 tubes
EUR 814.32

Galanin-Like Peptide (GALP) (Human)

026-51 100 μg
EUR 230.04

PACAP-Related Peptide (PRP) (Human)

052-10 200 μg
EUR 86.4

Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human)

064-07 200 μg
EUR 114.48

T3 Peptide / Tumstatin (69-88) (Human)

016-50 100 μg
EUR 255.96

T7 Peptide / Tumstatin (74-98) (Human)

016-51 100 μg
EUR 255.96

Galanin-Like Peptide (GALP) (36-60) (Human) - Antibody

H-026-55 50 μl
EUR 604.8

Peptide YY (PYY) (1-36)-Gly (Human)

059-07 100 μg
EUR 295.92

Peptide YY (PYY) (3-36)-Gly (Human)

059-08 100 μg
EUR 282.96

Peptide YY (PYY) (2-36)-Gly (Human)

059-11 100 μg
EUR 267.84

Peptide YY (PYY) (4-36)-Gly (Human)

059-12 100 μg
EUR 267.84

Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - Purified IgG Antibody

G-064-07 400 μg
EUR 438.48

Gastrin Releasing Peptide (GRP) (Human)

027-07 200 μg
EUR 119.88

Peptide YY (PYY) (3-36) (Human) - Purified IgG Antibody

G-059-02 200 μg
EUR 604.8

Prolactin-Releasing Peptide-31 (PrRP-31) (Human) - Antibody

H-008-50 50 μl
EUR 604.8

SHAAG Peptide / Chemokine (46-63) (Human)

072-32 100 μg
EUR 160.92

Stresscopin Related Peptide (SRP) (Human)

019-27 100 μg
EUR 214.92

Fractalkine Chemokine Domain peptide (41-52) (Human)

026-82 200 μg
EUR 160.92

Fractalkine Chemokine Domain peptide (53-60) (Human)

026-83 200 μg
EUR 135

Fractalkine Chemokine Domain peptide (60-71) (Human)

026-84 200 μg
EUR 160.92

C28 optimized peptide 15 Dimer (Human)

073-86 100 μg
EUR 420.12

RFamide-Related Peptide 3 (RFRP-3) (Human) - Antibody

H-048-46 100 μl
EUR 604.8

Osteoblast Activating Peptide (OBAP) (Human)

055-52 100 μg
EUR 199.8

Human Proteome Signature Peptide Library

L-010 98 peptides
EUR 7804.08

Peptide YY (PYY) (3-36) (Human) - EIA Kit

EK-059-02 96 wells
EUR 617.76

Peptide YY (PYY) (3-36) (Human) - RIA Kit

RK-059-02 125 tubes
EUR 814.32

Nesfatin-1-Like Peptide (NLP) (Human)

009-83 100 μg
EUR 469.8

APP 17mer peptide / APP770 (204-220) (Human)

018-74 100 μg
EUR 135

Urotensin II Related Peptide (Human, Rat, Mouse) - Antibody

H-071-17 50 μl
EUR 604.8

C28 optimized peptide 15 Monomer (Human)

073-84 100 μg
EUR 258.12

Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - RIA Kit

RK-064-07 125 tubes
EUR 932.04

Peptide YY (PYY) (Human) - I-125 Labeled

T-059-01 10 μCi
EUR 1145.88

Defensin I / Human Neutrophil Peptide-1 (HNP-1) (Human)

072-17 100 μg
EUR 370.44

Galanin-Like Peptide (GALP) (Human) - Purified IgG Antibody

G-026-51 200 μg
EUR 604.8

SHLP1 / Small Humanin-Like Peptide 1 (Human)

018-75 100 μg
EUR 263.52

SHLP2 / Small Humanin-Like Peptide 2 (Human)

018-76 100 μg
EUR 263.52

SHLP3 / Small Humanin-Like Peptide 3 (Human)

018-77 100 μg
EUR 422.28

SHLP4 / Small Humanin-Like Peptide 4 (Human)

018-78 100 μg
EUR 289.44

SHLP5 / Small Humanin-Like Peptide 5 (Human)

018-79 100 μg
EUR 316.44

SHLP6 / Small Humanin-Like Peptide 6 (Human)

018-80 100 μg
EUR 250.56

Galanin-Like Peptide (GALP) (36-60) (Human)

026-55 200 μg
EUR 177.12

FGF23 (188-199 )optimized peptide 10 (Human)

073-88 100 μg
EUR 258.12

Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - FAM Labeled

FG-064-07A 1 nmol
EUR 336.96

Mast Cell-Degranulating Peptide (MCD Peptide) / Peptide 401

004-04 100 μg
EUR 140.4

Peptide YY (PYY) (3-36) (Human) - FAM Labeled

FG-059-02A 1 nmol
EUR 336.96

Prolactin-Releasing Peptide-31 (PrRP-31) (Human)

008-50 200 μg
EUR 199.8

Prolactin-Releasing Peptide-20 (PrRP-20) (Human)

008-51 200 μg
EUR 199.8

Gastrin Releasing Peptide (GRP) (Human) - Purified IgG Antibody

G-027-07 400 μg
EUR 438.48

Agouti-Related Peptide (AgRP) (83-132) amide (Human) - Antibody

H-003-53 50 μl
EUR 469.8

Agouti-Related Peptide (AgRP) (25-51) (Human)

003-51 200 μg
EUR 129.6

Agouti-Related Peptide (AgRP) (54-82) (Human)

003-52 200 μg
EUR 129.6

Agouti-Related Peptide (AgRP) (25-82) (Human)

003-74 100 μg
EUR 497.88

Gastrin Releasing Peptide (GRP) (18-27) (Human)

027-41 200 μg
EUR 160.92

Gastrin Releasing Peptide (GRP) (1-16) (Human)

027-08 1 mg
EUR 177.12

Gastrin Releasing Peptide (GRP) (1-17) (Human)

027-42 200 μg
EUR 189

Seminal Plasma Inhibin-Like Peptide (Human)

034-03 200 μg
EUR 194.4

Galanin-Like Peptide (GALP) (Human) - RIA Kit

RK-026-51 125 tubes
EUR 932.04

Stresscopin Related Peptide (SRP) (Human) - Purified IgG Antibody

G-019-27 200 μg
EUR 604.8

Peptide YY (PYY) (3-36) (Human) - Biotin Labeled

B-059-02 10 μg
EUR 405

Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - I-125 Labeled

T-064-07 10 μCi
EUR 1145.88

RFamide-Related Peptide 1 (RFRP-1) (Human)

048-42 500 μg
EUR 177.12

RFamide-Related Peptide 2 (RFRP-2) (Human)

048-44 500 μg
EUR 177.12

RFamide-Related Peptide 3 (RFRP-3) (Human)

048-46 500 μg
EUR 177.12

Gastrin Releasing Peptide (GRP) (Human) - EIA Kit

EK-027-07 96 wells
EUR 603.72

Gastrin Releasing Peptide (GRP) (Human) - RIA Kit

RK-027-07 125 tubes
EUR 932.04

Prolactin-Releasing Peptide-31 (PrRP-31) (Human) - Purified IgG Antibody

G-008-50 400 μg
EUR 604.8

Urotensin II Related Peptide (Human, Rat, Mouse)

071-17 200 μg
EUR 129.6

Peptide YY (PYY) (3-36) (Human) - I-125 Labeled

T-059-02 10 μCi
EUR 1145.88

Galanin-Like Peptide (GALP) (36-60) (Human) - Purified IgG Antibody

G-026-55 200 μg
EUR 604.8

[Tyr0]-pro-Gastrin Releasing Peptide (GRP) (80-97) (Human) - Antibody

H-027-36 100 μl
EUR 370.44

T3 Peptide / Tumstatin (69-88) (Human) - FAM Labeled

FG-016-50A 1 nmol
EUR 469.8

T7 Peptide / Tumstatin (74-98) (Human) - FAM Labeled

FG-016-51A 1 nmol
EUR 469.8

Peptide YY (PYY) (3-36) (Human) - Rhodamine Labeled

FR-059-02 1 nmol
EUR 405

Galanin-Like Peptide (GALP) (Human) - FAM Labeled

FG-026-51A 1 nmol
EUR 604.8

Stresscopin Related Peptide (SRP) (Human) - RIA Kit

RK-019-27 125 tubes
EUR 1341.36

[Tyr0]-Agouti-Related Peptide (AgRP) (25-51) (Human)

003-72 100 μg
EUR 416.88

[Tyr0]-Agouti-Related Peptide (AgRP) (54-82) (Human)

003-73 100 μg
EUR 416.88

R3 (BDelta23-27) R / I5 Chimeric Peptide (Human)

035-66 100 μg
EUR 604.8

Nesfatin-1-Like Peptide(NLP) (Human) - RIA Kit

RK-009-83 125 tubes
EUR 980.64

Gastrin Releasing Peptide-Gly (GRP-Gly) (Human)

027-37 100 μg
EUR 160.92

[Leu(13C)6,(15N)-15,22]-Peptide YY (PYY) (3-36) (Human)

SIL-059-02 20 μg
EUR 1186.92

pro-Gastrin Releasing Peptide (GRP) (42-98) (Human)

027-34 100 μg
EUR 355.32

pro-Gastrin Releasing Peptide (GRP) (47-68) (Human)

027-35 100 μg
EUR 160.92

SHAAG Peptide / Chemokine (46-63) (Human) - Cy3 Labeled

FC3-072-32 1 nmol
EUR 587.52

SHAAG Peptide / Chemokine (46-63) (Human) - Cy5 Labeled

FC5-072-32 1 nmol
EUR 587.52

SHAAG Peptide / Chemokine (46-63) (Human) - FAM Labeled

FG-072-32A 1 nmol
EUR 267.84

7B2 Carboxyl-terminal (CT) peptide (Human, Porcine)

004-32 100 μg
EUR 160.92

Osteoblast Activating Peptide (OBAP) (Human) - EIA Kit

EK-055-52 96 wells
EUR 660.96

Osteoblast Activating Peptide (OBAP) (Human) - RIA Kit

RK-055-52 125 tubes
EUR 980.64

Peptide YY (PYY) (3-36) (Human) - MagBead (Magnetic Bead Linked Antibody)

MB-059-02 1 ml
EUR 842.4

Peptide YY (PYY) (3-36) (Human) - Fluorescent EIA Kit

FEK-059-02 96 wells
EUR 660.96

prepro-Galanin-Like Peptide (GALP) (87-116) (Human)

026-54 200 μg
EUR 230.04

prepro-RFamide Related Peptide (RFRP) (56-92) amide (Human) - Antibody

H-048-54 100 μl
EUR 604.8

prepro-RFamide Related Peptide (RFRP) (115-131) amide (Human) - Antibody

H-048-55 50 μl
EUR 604.8

Stresscopin Related Peptide (SRP) (Human) - FAM Labeled

FG-019-27A 1 nmol
EUR 537.84

Agouti-Related Peptide (AgRP) (83-132) amide (Human)

003-53 100 μg
EUR 316.44

Agouti-Related Peptide (AgRP) (71-132), Form C amide (Human) - Antibody

H-003-55 50 μl
EUR 604.8

Gastrin Releasing Peptide (GRP) (14-27) (Human, Porcine)

027-16 500 μg
EUR 108

[Tyr0]-RFamide-Related Peptide 1 (RFRP-1) (Human)

048-43 200 μg
EUR 177.12

[Tyr0]-RFamide-Related Peptide 2 (RFRP-2) (Human)

048-45 200 μg
EUR 177.12

[Tyr0]-RFamide-Related Peptide 3 (RFRP-3) (Human)

048-47 200 μg
EUR 177.12

Prolactin-Releasing Peptide-31 (PrRP-31) (Human) - EIA Kit

EK-008-50 96 wells
EUR 603.72

Prolactin-Releasing Peptide-31 (PrRP-31) (Human) - RIA Kit

RK-008-50 125 tubes
EUR 932.04

Parathyroid Hormone-Like Peptide (PLP) (140-173) (Human)

056-17 200 μg
EUR 129.6

SHAAG Peptide / Chemokine (46-63) (Human) - Biotin Labeled

B-072-32 10 μg
EUR 267.84

Urotensin II Related Peptide (Human, Rat, Mouse) - Purified IgG Antibody

G-071-17 200 μg
EUR 604.8

Galanin-Like Peptide (GALP) (Human) - Rhodamine Labeled

FR-026-51 1 nmol
EUR 604.8

Galanin-Like Peptide (GALP) (Human) - I-125 Labeled

T-026-51 10 μCi
EUR 1145.88

Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - I-125 Labeled Purified IgG

T-G-064-07 10 μCi
EUR 1145.88

The literature on the topic is limited: only eight papers were eligible were identified and reviewed. The rated focuses on four domains: requirements / needs, actual costs, patient safety and outcomes, and education and training. Most of the advantages / benefits of the proposed clinic had previously been discussed. The current review has revealed that the published evidence available on the clinical concept OMFS H & N nurse led indicate that they may not be necessary.

Related Posts

Leave a Reply

Your email address will not be published.